Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine

被引:17
作者
Martini, Caroline [1 ]
Buxbaum, Sabine [2 ]
Rodrigues, Margarida [2 ]
Nilica, Bernhard [2 ]
Scarpa, Lorenza [2 ]
Holzner, Bernhard [1 ,3 ]
Virgolini, Irene [2 ]
Gamper, Eva-Maria [4 ]
机构
[1] Med Univ Innsbruck, Dept Psychiat Psychotherapy & Psychosomat, Psychiat 1, Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Nucl Med, Innsbruck, Austria
[3] Med Univ Innsbruck, Dept Psychiat Psychotherapy & Psychosomat, Psychiat 2, Innsbruck, Austria
[4] IIPCOR, Dr Stumpf Str 56, A-6020 Innsbruck, Austria
基金
奥地利科学基金会;
关键词
gastroenteropancreatic neuroendocrine tumors; peptide receptor radionuclide therapy; health-related quality of life; clinical practice; routine monitoring; CARCINOID-TUMORS; REPORTED OUTCOMES; ENDOCRINE TUMORS; HEALTH; MANAGEMENT; GENDER; LU-177-DOTATATE; EPIDEMIOLOGY; DEPRESSION; EVEROLIMUS;
D O I
10.2967/jnumed.117.204834
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with metastatic gastroenteropancreatic neuroendocrine tumors (NETs), we evaluated health-related quality of life (HRQoL) from the first peptide receptor radionuclide therapy (PRRT) to the first restaging and compared the scores with general-population (GP) norms. Methods: The data were from routine HRQoL monitoring using the core quality-of-life questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30). Patients received 4-6 cycles of 177Lu-DOTATATE or Y-90-DOTATOC. To be eligible for analysis, patients had to have at least one HRQoL assessment before PRRT and at least one HRQoL assessment at the end of or after treatment completion. Linear mixed models were used to consider HRQoL changes over time. Results: In total, 61 gastroenteropancreatic NET patients (small-intestine NETs, n = 37; pancreatic NETs, n = 24) were eligible for analysis. Clear improvements from baseline to the first restaging were found for diarrhea in small-intestine NET patients, showing a decrease of 16 points, which represents a moderately large change. We observed a clinically relevant decrease in appetite loss (17 points), but for female small-intestine NET patients only. Other HRQoL changes were also restricted to sociodemographic or clinical subgroups and mainly reflected improvements, except for physical and social functioning, which showed decreasing scores in older small-intestine NET patients. Compared with HRQoL GP norms, patients had impairments consisting of diarrhea; fatigue; appetite loss; reduced physical, social, and role functioning; and reduced global HRQoL. Except for diarrhea and appetite loss, patient scores at the first restaging did not reach GP levels. Conclusion: Our analyses support previous findings of overall stable HRQoL under PRRT. Yet, significant HRQoL impairments compared with the GP and potentially specific subgroup patterns need to be considered.
引用
收藏
页码:1566 / 1573
页数:8
相关论文
共 57 条
[11]   Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study [J].
Cwikla, J. B. ;
Sankowski, A. ;
Seklecka, N. ;
Buscombe, J. R. ;
Nasierowska-Guttmejer, A. ;
Jeziorski, K. G. ;
Mikolajczak, R. ;
Pawlak, D. ;
Stepien, K. ;
Walecki, J. .
ANNALS OF ONCOLOGY, 2010, 21 (04) :787-794
[12]   Peptide Receptor Radionuclide Therapy: An Overview [J].
Dash, Ashutosh ;
Chakraborty, Sudipta ;
Pillai, Maroor Raghavan Ambikalmajan ;
Knapp, Furn F. , Jr. .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2015, 30 (02) :47-71
[13]   Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience [J].
Delpassand, Ebrahim S. ;
Samarghandi, Amin ;
Zamanian, Sara ;
Wolin, Edward M. ;
Hamiditabar, Mohammadali ;
Espenan, Gregory D. ;
Erion, Jack L. ;
O'Dorisio, Thomas M. ;
Kvols, Larry K. ;
Simon, Jaime ;
Wolfangel, Robert ;
Camp, Arthur ;
Krenning, Eric P. ;
Mojtahedi, Alireza .
PANCREAS, 2014, 43 (04) :518-525
[14]  
Devlin N., 2010, Getting the most out of PROMS: putting health outcomes at the heart of the NHS decision-making
[15]  
Fayers P., 2001, EORTC QLQ-C30 scoring manual
[16]   Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors [J].
Frilling, Andrea ;
Weber, Frank ;
Saner, Fuat ;
Bockisch, Andreas ;
Hofmann, Michael ;
Mueller-Brand, Jan ;
Broelsch, Christoph E. .
SURGERY, 2006, 140 (06) :968-976
[17]   Multimodal management of neuroendocrine liver metastases [J].
Frilling, Andrea ;
Sotiropoulos, Georgios C. ;
Li, Jun ;
Kornasiewicz, Oskar ;
Ploeckinger, Ursula .
HPB, 2010, 12 (06) :361-379
[18]   Health related quality of life and psychosocial function among patients with carcinoid tumours.: A longitudinal, prospective, and comparative study [J].
Frojd, Camilla ;
Larsson, Gunnel ;
Lampic, Claudia ;
von Essen, Louise .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2007, 5 (1)
[19]   Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme [J].
Gamper, Eva-Maria ;
Wintner, Lisa M. ;
Rodrigues, Margarida ;
Buxbaum, Sabine ;
Nilica, Bernhard ;
Singer, Susanne ;
Giesinger, Johannes M. ;
Holzner, Bernhard ;
Virgolini, Irene .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (08) :1179-1188
[20]   Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach [J].
Gelhorn, Heather L. ;
Kulke, Matthew H. ;
O'Dorisio, Thomas ;
Yang, Qi M. ;
Jackson, Jessica ;
Jackson, Shanna ;
Boehm, Kristi A. ;
Law, Linda ;
Kostelec, Jacqueline ;
Auguste, Priscilla ;
Lapuerta, Pablo .
CLINICAL THERAPEUTICS, 2016, 38 (04) :759-768